Laboratorios Lesvi, S.l.

Glòria Freixas Pascual

Pere Dalmases Barjoan

Jordi Cerón Bertran

Juan Huguet Clotet

Jordi Benet-Buchholz

Jordi Bessa Bellmunt

Lluis Sola Carandell

Jordi Carles Ceron Bertran

Isabel Navarro Muñoz

Lluis Solà Carandell

Pere Dalmases

Antonio Abelino De Leon Martin

Isabel Navarro MUÑOZ

Lluís Sola Carandell

Antonio Abelino De León Martín

A monoclinic crystalline form of asenapine maleate is described, which is characterized in that it is not micronised and has a particle size distribution characterized by a d90 of 40 &#x3bc;m or less. A process for the preparation of a monoclinic crystalline form of asenapine maleate is also described, the process comprising the following steps: a) providing a mixture of monoclinic asenapine maleate and an organic solvent which, under the conditions of the process, acts as an antisolvent; b) stirring the mixture at a temperature between 15 and 60&#xb0; C.; and c) collecting the crystals, wherein the organic solvent is selected from alcohols, ketones, ethers, esters, hydrocarbons or mixtures thereof.

Monoclinic crystalline form of asenapine maleate with a specific particle size distribution

New polymorphic form of a long-acting beta-2 adrenoceptor agonist A new polymorphic form of arformoterol tartrate, designated as form D, is provided and which is characterized by at least one of the following: (i) a powder X-ray diffraction pattern having peaks at approximately 6.8, 13.3, 13.6, 3.8, 14.1, 18.2, 18.7, 20.0&#xb1;0.2 degrees two theta; or (ii) a DSC thermogram showing an endothermic peak with an onset at approximately 19-120&#xb0; C., and a maximum at approximately 129-131&#xb0; C., followed by an exothermic peak with a maximum at approximately 137-138&#xb0; C.; wherein the DSC thermogram of form D has a further endothermic peak with an onset at approximately 168-170&#xb0; C.1 Processes for preparing the new polymorphic form, uses thereof and intermediates for the preparation thereof, are also provided.

Polymorphic form of a long-acting beta-2 adrenoceptor agonist

The present invention refers to an improved method for the preparation of compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid substantially free of its 3H-I isomer. The invention also refers to the use of said intermediate for the preparation of Rufinamide and for obtaining a new polymorphic form of Rufinamide, designed as Form R-5. The invention also refers to said new polymorph of Rufinamide, and to the composition containing it and its use as medicament. The new polymorph of Rufinamide shows good stability and appropriate physico-chemical properties for its manipulation on industrial scale. Polymorph Form R-5 will be suitable to use as pharmaceutical for the treatment of convulsions, especially for the treatment of epilepsy.

Process for preparing rufinamide intermediate

Growing community of inventors

Tarragona, Spain

Glòria Freixas Pascual